ArticleJournal of Alzheimer's disease reports
DNA methylation in peripheral blood leukocytes in late onset Alzheimer's disease.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic-Epigenetic Crosstalk in Takayasu Arteritis: The ANK2-MAVS-IL-8 Axis as a Novel Therapeutic Paradigm.International journal of molecular sciences · 2026Review
- DNA methylation signature of cognitive reserve moderates CSF tau pathology in prodromal Alzheimer's disease.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic systemic inflammation is implicated in Alzheimer's disease (AD) pathogenesis and has measurable effects on blood cells. There is increasing interest in non-invasive diagnostic tools that use blood-based biomarkers for AD, such as DNA methylation. Notably, DNA methylation changes in blood are also linked to systemic inflammation. The evaluation of DNA methylation profiles in peripheral blood leukocytes as potential biomarkers for AD is promising. Objective: To determine DNA methylation patterns in blood for AD, and to explore specific blood CpG sites that act as surrogates for brain-tissue methylation. Methods: DNA methylation data from peripheral blood leukocytes of AD patients and controls were obtained from the Gene Expression Omnibus (GSE59685 and GSE53740). Differential methylation analysis was performed for individual CpGs Differentially methylated positions (DMPs) and regions with multiple probes (DMRs) and the intersection analysis of DMPs and DMRs was conducted. Functional enrichment analysis highlights relevant biological processes. Furthermore, previously validated specific CpGs used as surrogate of brain tissue were explored. Results: DNA methylation patterns included Conclusions: This study identified DNA methylation patterns in peripheral blood leukocytes as potential biomarkers for AD. These findings offer insights into epigenetic mechanisms associated with systemic peripheral inflammation in AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.